05:31 , May 2, 2019 |  BC Extra  |  Company News

AstraZeneca adds oncolytic virus option through Transgene deal

AstraZeneca is taking another look at oncolytic viruses through an option deal with French biotech Transgene. On Thursday, the partners said AstraZeneca plc (LSE:AZN; NYSE:AZN) would receive an exclusive option to co-develop and commercialize five...
18:43 , Jan 18, 2019 |  BC Week In Review  |  Company News

Bayer to increase patient access to specialty drugs with ZappRx digital platform

Bayer AG (Xetra:BAYN) gained access to a digital platform from ZappRx Inc. (Boston, Mass.) to improve patient access to Bayer's specialty drugs for pulmonary hypertension and relapsing-remitting multiple sclerosis (RRMS). ZappRx founder and CEO Zoë...
13:04 , Jan 16, 2019 |  BC Extra  |  Company News

Bayer to increase patient access to specialty drugs with ZappRx digital platform

Bayer AG (Xetra:BAYN) gained access to a digital platform from ZappRx Inc. (Boston, Mass.) to improve patient access to Bayer's specialty drugs for pulmonary hypertension and relapsing-remitting multiple sclerosis (RRMS). ZappRx founder and CEO Zoë...
03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
15:55 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Other

INDICATION: Genetic disorders Cell culture and mouse studies identified a covalent STING inhibitor that could help treat Aicardi-Goutières syndrome, an inflammatory disorder is caused by mutations in one of seven genes, including TREX1. Screening of...
21:12 , Apr 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Cell culture and mouse studies suggest inhibiting MLL5 could help treat RNA viral infections. In primary mouse macrophages infected with vesicular stomatitis virus (VSV) or Sendai virus, knockout of MLL5 decreased levels...
21:12 , Mar 7, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Engineered viruses A method for enhancing viral sensitivity to host IFN could be used to generate highly immunogenic, live virus-based vaccines against infection. The approach involves using saturation mutagenesis and next-generation sequencing to compare...
23:23 , Feb 28, 2018 |  BC Innovations  |  Translation in Brief

Interferon non-interference

Researchers from UCLA have developed a method to enhance the immunogenicity of live virus-based vaccines by inactivating the virus’ ability to evade interferon-mediated host immunity. Having shown proof-of-concept for an influenza A vaccine, the team...
19:29 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and cell culture studies suggest IFNB1 could help treat breast cancer. In breast tissue samples from patients with invasive ductal carcinoma, levels of IFNB1 were higher in tumors than in...
01:19 , Jan 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Age-related macular degeneration (AMD) Patient sample, cell culture and mouse studies suggest inhibiting cGAS, CASP4, GSDMD, IFNB1, IFNAR1, IRF3 or STAT2 could help treat geographic atrophy. In tissue samples from patients, levels of cGAS,...